Description
Proteostasis Therapeutics Inc is a United States-based clinical-stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis (CF) through theratyping, or the process of matching modulators to individual response to treatment regardless of cystic fibrosis transmembrane conductance regulator (CFTR) mutations. All of the company's revenue is collaboration or license revenue earned from activities in the United States.
